tcsc7377 Tetrahydrocannabivarin

Tetrahydrocannabivarin is a cannabinoid type 1 (CB1) receptor neutral antagonist, with possible therapeutic activity for type 2 diabetes.

In Vitro: Tetrahydrocannabivarin is more potent for antagonizing the effect of WIN and anandamide on electrically induced contractions of the vas deferens than provoking the inhibition initiated by THC. THCV (3-1000 nM) does not prevent electrically induced contractions of mouse isolated vas deferens. However, THCV (3 mM) does lessens the contractile reaction of the vas deferens in a CB1 receptor antagonist (SR141716)-independent way. Moreover, THCV cooperates with non-CB1 targets at high quantities^[1].